Applying PCSK9 Inhibitors to Improve Outcomes and the Overall Quality of Life for Patients With Dyslipidemia

http://academiccme.com/wp-content/uploads/2017/12/910755-125-x-125-wpcf_400x400.jpg

Course Information

Therapautic Area:
Format(s): Meeting Reporter
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: December 20, 2017 to December 19, 2018

 

Program Overview

This conference reporter will cover data presented at the American Heart Association (AHA) Scientific Session 2017 held in Anaheim, California. The expert faculty will discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia including achieving LDL-C goals, cardiovascular risk reduction and managing special patient populations. Current and emerging clinical trial data of PCSK9 inhibitors will be analyzed. The faculty will discuss different approaches of how to implement newer therapies into individualized treatment plans. Upon completing this activity, clinicians will gain a better understanding of treatment options to provide better outcomes for patients with dyslipidemia.

Target Audience

This activity has been designed to meet the educational needs of cardiologists, primary care physicians, and other healthcare professionals who care for patients with dyslipidemia.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia, including cardiovascular risk reduction, achieving LDL-C goals and managing special patient populations.
  2. Analyze clinical trial data of current and emerging PCSK9 inhibitors for the treatment of dyslipidemia, as presented at AHA 2017.
  3. Incorporate newer therapies into individualized treatment plans to improve outcomes for patients with dyslipidemia.

Faculty

Cannon Headshot

Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

 

Blaha_Headshot

Michael J. Blaha, MD, MPH
Associate Professor of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins College of Medicine
Baltimore, Maryland

 

 

marc-sabatine

Marc S. Sabatine, MD
Chairman, TIMI Study Group Senior Physician
Division of Cardiovascular Medicine
BWH Professor of Medicine
Harvard Medical School
Boston, Massachusetts

 

 

stephen-wiviottStephen D. Wiviott, MD
Cardiovascular Division
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, Massachusetts

 

 



 

Registration

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

eocme acme logo